QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

K. N. Moore, A. A. Secord, M. Geller, D. S. Miller, N. G. Cloven, G. F. Fleming, A. E. Wahner Hendrickson, M. Azodi, P. DiSilvestro, A. Oza, M. Cristea, J. S. Berek, J. K. Chan, B. J. Rimel, Y. Li, K. Luptakova, R. Clark, U. A. Matulonis, B. J. Monk

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii337
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Moore, K. N., Secord, A. A., Geller, M., Miller, D. S., Cloven, N. G., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A., Cristea, M., Berek, J. S., Chan, J. K., Rimel, B. J., Li, Y., Luptakova, K., Clark, R., Matulonis, U. A., & Monk, B. J. (2018). QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii337. https://doi.org/10.1093/annonc/mdy285.152